There has been an increase in the number of breast cancer cases in the UK. As many as 3,800 women were reported to have been diagnosed with the ductal carcinoma in situ (DCIS) during 2002. The Cancer Research UK is engaged in finding out which of the hormone therapy drugs are capable of preventing the recurrence of the disease. The benefits derived from both tamoxifen and anastrozole are being studied. The DCIS is considered a pre-cancerous condition, which can later develop into invasive cancer.
The best therapy for the condition has not been decided upon as yet. Many women are not taking drugs which are capable of preventing the cancer from returning. Anastrozole is reported to be more effective than tamoxifen when it comes to reducing the recurrence of the disease, and the former is also capable of preventing the recurrence of 80% of these tumors. The DCIS trial has attracted as many as 20 nations across 42 centers in Britain. The breast screening programs are capable of detecting the DCIS. When the cells belonging to the breast's milk ducts become cancerous, the condition is said to occur. As many as 10,000 women will be recruited by the Ibis-2 study, of whom about 4,000 have already been diagnosed with the DCIS.